A Phase 1 interventional study of rozanolixizumab and Placebo in Healthy Study Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single subcutaneous (SC) dose of rozanolixizumab administered to healthy participants by manual push (MP) versus (vs) syringe driver.
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
Drug: rozanolixizumab · Other: Placebo
Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
Drug: rozanolixizumab · Other: Placebo
Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
Drug: rozanolixizumab · Other: Placebo
Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
Drug: rozanolixizumab · Other: Placebo
Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.
Also known as: RLZ
Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.
Also known as: PBO
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event (AE) with a start date/time on or after first dose of study medication until 8 weeks after dosing of study medication.
Time frame: From start of dosing (Day 1) to End of Safety Follow-Up (up to Day 57)
Maximum Plasma Concentration (Cmax) of a Single Dose Rozanolixizumab
Cmax was the maximum plasma concentration of a single dose rozanolixizumab. Cmax was measured in micrograms per millilitre per milligram (ug/mL/mg).
Time frame: Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16
Time to Maximum Plasma Concentration (Tmax) of a Single Dose Rozanolixizumab
tmax was the time to maximum plasma concentration of a single dose rozanolixizumab.
Time frame: Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16
Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t) of a Single Dose Rozanolixizumab
AUC0-t was the area under the plasma concentration-time curve from time zero to time t of a single dose rozanolixizumab.
Time frame: Sampling time points for plasma Pharmacokinetics were as follows: predose, immediately at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, and 16
Baseline-corrected Area Under the Total Immunglobulin (Ig) G-time Curve
Area under the baseline-corrected total IgG response curve from time 0 to time t.
Time frame: Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57
Percent Maximum Decrease in Total Plasma IgG (Rmin) of a Single Dose Rozanolixizumab or Placebo
Rmin was the maximum (max) decrease in total plasma IgG of a single dose rozanolixizumab or placebo.
Time frame: Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57
Time to Minimum IgG Level (Tmin) of a Single Dose Rozanolixizumab or Placebo
tmin was the time to minimum IgG level of a single dose rozanolixizumab or placebo.
Time frame: Sampling time points for total IgG were as follows: 24, 36, 48, 72, and 96 hours after start of infusion, and on Days 7, 10, 13, 16, 19, 22, 29, 43 and 57
The study started to enroll participants in April 2021 and concluded in April 2022.
| Milestone | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 2 | 6 | 2 | 6 | 2 | 6 | 2 |
| Completed | 6 | 2 | 6 | 2 | 6 | 2 | 6 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A TEAE was defined as any adverse event (AE) with a start date/time on or after first dose of study medication until 8 weeks after dosing of study medication.
| percentage of participants | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 83.3 | 50.0 | 100 | 50.0 | 83.3 | 0 | 83.3 | 100 |
Cmax was the maximum plasma concentration of a single dose rozanolixizumab. Cmax was measured in micrograms per millilitre per milligram (ug/mL/mg).
| ug/mL/mg | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of a Single Dose Rozanolixizumab | 0.03352 ± 52.8 | 0.004066 ± 127.0 | 0.007293 ± 644.1 | 0.02752 ± 82.2 |
tmax was the time to maximum plasma concentration of a single dose rozanolixizumab.
| hours | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) |
|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of a Single Dose Rozanolixizumab | 60.10 (36.0 to 72.4) | 48.03 (36.0 to 72.1) | 72.00 (36.0 to 96.3) | 72.00 (36.0 to 96.1) |
AUC0-t was the area under the plasma concentration-time curve from time zero to time t of a single dose rozanolixizumab.
| hours*ug/mL/mg | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t) of a Single Dose Rozanolixizumab | 2.408 ± 55.4 | 0.1436 ± 266.7 | 0.4223 ± 687.0 | 2.111 ± 80.5 |
Area under the baseline-corrected total IgG response curve from time 0 to time t.
| grams*day/Litre (g*day/L) | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) |
|---|---|---|---|---|---|---|---|---|
| Baseline-corrected Area Under the Total Immunglobulin (Ig) G-time Curve | -190.6 ± 66.10 | NA ± NA | -101.0 ± 118.4 | NA ± NA | -141.8 ± 52.99 | NA ± NA | -168.8 ± 49.70 | NA ± NA |
Rmin was the maximum (max) decrease in total plasma IgG of a single dose rozanolixizumab or placebo.
| percent max decrease in total plasma IgG | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) |
|---|---|---|---|---|---|---|---|---|
| Percent Maximum Decrease in Total Plasma IgG (Rmin) of a Single Dose Rozanolixizumab or Placebo | -46.73 ± 14.76 | NA ± NA | -42.14 ± 13.31 | NA ± NA | -44.03 ± 8.711 | NA ± NA | -42.90 ± 10.67 | NA ± NA |
tmin was the time to minimum IgG level of a single dose rozanolixizumab or placebo.
| days | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) |
|---|---|---|---|---|---|---|---|---|
| Time to Minimum IgG Level (Tmin) of a Single Dose Rozanolixizumab or Placebo | 12.08 (8.98 to 42.0) | NA (6.08 to 9.16) | 11.07 (6.11 to 15.1) | NA (4.00 to 42.1) | 9.012 (5.97 to 12.1) | NA (5.96 to 15.1) | 10.55 (4.00 to 15.0) | NA (2.00 to 8.95) |
Collected over From start of dosing (Day 1) to End of Safety Follow-Up (up to Day 57). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 3: Syringe Driver- PBO (>=50 kg) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 4: Manual Push- PBO (>=50 kg) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 4/6 | 0/2 | 3/6 | 0/2 | 2/6 | 0/2 | 2/6 | 1/2 |
| Abdominal pain upperGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 1/2 | 1/6 | 0/2 | 0/6 | 0/2 |
| Gingival bleedingGastrointestinal disorders | 0/6 | 1/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 |
| NauseaGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 1/2 | 1/6 | 0/2 | 0/6 | 0/2 |
| Infusion site erythemaGeneral disorders | 3/6 | 0/2 | 2/6 | 0/2 | 1/6 | 0/2 | 1/6 | 0/2 |
| PyrexiaGeneral disorders | 2/6 | 0/2 | 0/6 | 1/2 | 3/6 | 0/2 | 0/6 | 0/2 |
| Aspartate aminotransferase increasedInvestigations | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 | 0/6 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 0/2 | 2/6 | 0/2 | 0/6 | 0/2 |
| VomitingGastrointestinal disorders | 0/6 | 0/2 | 0/6 | 0/2 | 2/6 | 0/2 | 0/6 | 0/2 |
| Infusion site painGeneral disorders | 2/6 | 0/2 | 1/6 | 0/2 | 0/6 | 0/2 | 0/6 | 0/2 |
Baseline Characteristics refer to the Safety Analysis Set which consisted of all randomized study participants who received investigational medicinal product (IMP).
| Age, Categorical(Participants) | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 2 | 6 | 2 | 6 | 2 | 6 | 2 | 32 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 36.7 ± 15.7 | NA ± NA | 33.2 ± 9.5 | NA ± NA | 39.3 ± 8.1 | NA ± NA | 45.5 ± 12.7 | NA ± NA | 37.4 ± 12.1 |
| Sex: Female, Male(Participants) | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 2 | 6 | 2 | 2 | 0 | 2 | 1 | 21 |
| Male | 0 | 0 | 0 | 0 | 4 | 2 | 4 | 1 | 11 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asian | 4 | 1 | 6 | 2 | 0 | 0 | 0 | 0 | 13 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 2 | 1 | 0 | 0 | 4 | 2 | 4 | 2 | 15 |
| Other or Mixed | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 3 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Syringe Driver- RLZ Dose 1 (>=35 kg to <50 kg) | Cohort 1: Syringe Driver- PBO (>=35 kg to <50 kg) | Cohort 2: Manual Push- RLZ Dose 2 (>=35 kg to <50 kg) | Cohort 2: Manual Push- PBO (>=35 kg to <50 kg) | Cohort 3: Syringe Driver- RLZ Dose 1 (>=50 kg) | Cohort 3: Syringe Driver- PBO (>=50 kg) | Cohort 4: Manual Push- RLZ Dose 1 (>=50 kg) | Cohort 4: Manual Push- PBO (>=50 kg) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 4 |
| Not Hispanic or Latino | 5 | 2 | 6 | 2 | 4 | 2 | 5 | 2 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Due to the small sample size in this trial, IPD cannot be adequately anonymized i.e., there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.
Ran from Apr 2021 to primary completion in Apr 2022, 11 months.
Results were first posted in Mar 2024, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab